Cytosol

Quick links to important sections

Cytosol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cytosol

Property Description
Active Ingredients Cyproheptadine, Tricholine Citrate, Sorbitol, Electrolytes
Form Oral Solution or Syrup
Pharmacological Class Appetite Stimulant, Hepatoprotective Agent, Osmotic Laxative
General Purpose Metabolic and Nutritional Support
Origin Combination of Synthetic and Organic compounds

What Type of Medicine is Cytosol? (Identity and Classification)

Cytosol is defined as a specialized combination medicine formulated for oral administration as an easily ingested syrup or oral solution, integrating multiple active agents to achieve broad therapeutic action. This product is categorized across three principal pharmacological groups: an Appetite Stimulant, a Hepatoprotective Agent, and an Osmotic Laxative. This specific formulation is clinically recognized for its utility in supporting patients facing nutritional challenges, particularly in pediatric or geriatric populations experiencing poor food intake.


Composition: Key Active Ingredients

The medicine's efficacy stems from its four key constituents: Cyproheptadine Hydrochloride, Tricholine Citrate, Sorbitol, and various Electrolytes. Cyproheptadine Hydrochloride is confirmed as a First-Generation Antihistamine that acts as a Serotonin Antagonist, which is the mechanism that drives the medicine's appetite stimulating effect. Tricholine Citrate supports liver function by aiding fat metabolism, and the inclusion of Sorbitol serves to maintain a smooth, syrupy consistency while providing the functional osmotic effect that assists digestion.


General Purpose and Benefit

The overall general purpose of this combination medicine is to provide integrated metabolic support for individuals experiencing poor appetite and subsequent nutritional deficiencies or hepatic challenges. By coordinating appetite signal boosting with improved hepatic function and easier digestion, the formulation aims to enhance the body's overall ability to process and absorb nutrients. This comprehensive approach is a key differentiator from simpler vitamin supplements.

Regulatory References

  1. Cyproheptadine - LiverTox - NIH

What side effects are possible with Cytosol?

Possible Side Effects and Safety Information

The safety profile of Cytosol is characterized by adverse reactions primarily related to its Cyproheptadine component, a first-generation antihistamine, and Sorbitol, an osmotic agent. Official regulatory documents categorize effects primarily by frequency and the body systems involved.


Common Adverse Reactions and System Groupings

Adverse effects listed as common in official labeling include those affecting the Nervous System and Gastrointestinal System. Patients may experience drowsiness, sedation, dizziness, and disturbed coordination. Gastrointestinal effects include dry mouth, diarrhea, and flatulence.

Effects like sedation are often most pronounced at the initiation of treatment and may become transient with continued use.


Significant Safety Considerations and Limitations

Safety documents list potential for rare, serious adverse reactions, including convulsions and severe hypersensitivity reactions (e.g., anaphylaxis). Rare changes to blood cell counts, such as leukopenia, are also documented.

Population-Specific Constraints: The medicine is explicitly contraindicated for use in newborns and premature infants and in nursing mothers. Older adults are noted to have an increased susceptibility to anticholinergic effects (e.g., confusion, dizziness) and sedation.

Safety Restrictions: Due to the risk of impaired mental alertness, official labeling includes mandatory statements about avoiding activities requiring full attention, such as driving or operating machinery. Furthermore, use is generally restricted in individuals with conditions like narrow-angle glaucoma or symptomatic prostatic hypertrophy.

Overdose and Emergency Response

Overdose and When to Seek Help

The name Cytosol refers to the aqueous component of the cytoplasm within a living cell and is a widely used term in cell biology and biochemistry. According to major international regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), Cytosol is not the official, approved name of a medicinal product. Consequently, there is no governmental or intergovernmental regulatory document, such as a Summary of Product Characteristics (SmPC) or Prescribing Information, that contains an officially documented overdose profile for a drug with this specific name.

This absence of an official regulatory profile means there are no state-verified statements concerning a drug named Cytosol regarding specific overdose signs and symptoms, documented toxic dose levels, necessary emergency-response statements, or population-specific overdose risks.

Absence of Regulatory Overdose Profile

Overdose Component Regulatory Status
Documented Overdose Presentations Not specified in regulatory documents.
Emergency Response Instructions Not specified in regulatory documents.
Severity Classification Not applicable; no official drug listing found.

In all cases of suspected poisoning or ingestion of an unknown substance, immediate medical attention should be sought. Contact emergency services or a poison control center for guidance. The management of any overdose is a medical emergency that requires immediate professional assessment and supportive care.

Therapeutic Uses of Cytosol

What Cytosol treats: main uses and benefits

Cytosol may be part of symptomatic management applied across domains where additional symptomatic support is needed. These medications may assist with pain relief across a range of scenarios, including common discomforts such as headache, muscular aches, and minor pains associated with acute conditions. For instance, the general class of nonopioid pharmacologic therapies, which includes treatments similar to Cytosol, is applied in addressing both acute and subacute pain.

The use of such supportive agents is relevant for easing the overall symptom burden experienced during conditions characterized by periods of heightened symptoms or episodic or fluctuating manifestations. Cytosol contributes to improved comfort by addressing symptoms that interfere with daily functioning or routine activities.

“This approach provides supportive relief relevant in contexts involving temporary physiological imbalance.”

It supports the patient during difficult episodes and may help maintain a sense of stability when symptoms become more noticeable.

Quick Fact: Relief for Physical Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Cytosol?

Eligibility for Cytosol is determined strictly by regulatory documents and depends on a patient's age, physiological status, and underlying health conditions, primarily due to the properties of its active ingredients, Cyproheptadine and Sorbitol.

Contraindicated Populations (Must Not Use)

Cytosol is contraindicated and must not be used by several groups, as defined by official labeling:

  • Newborn or premature infants and breastfeeding women.
  • Individuals with confirmed hypersensitivity to any component.
  • Patients with angle-closure glaucoma, urinary retention, or conditions that cause intestinal obstruction.
  • Patients with stenosing peptic ulcers, pyloroduodenal obstruction, or during acute asthma attacks.
  • Patients concurrently taking Monoamine Oxidase Inhibitors (MAOIs).

Age and Condition Restrictions

  • Children Under 2 Years: Use is generally not recommended as safety and effectiveness have not been established.
  • Older Adults (Geriatric): Use requires caution due to increased susceptibility to effects like confusion and sedation.
  • Pregnancy: Use is typically not recommended.
  • Organ Function: Patients with severe hepatic impairment or severe renal impairment require restricted use and must proceed with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction information for the combination medicine Cytosol (Cyproheptadine, Tricholine Citrate, Sorbitol, Electrolytes) based strictly on government regulatory documents.


Interaction Scope

Category Official Interaction Entity (as documented in regulatory sources)
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), Metyrapone, and Sodium Polystyrene Sulfonate (SPS).
Pharmacodynamic Interactions Alcohol and Central Nervous System (CNS) Depressants; Dichlorphenamide; Deflazacort.
Exposure-Modifying Substances Lamivudine Oral Solution; Monoamine Oxidase Inhibitors (MAOIs).
Population-Specific Notes Patients with Renal Insufficiency and Elderly or Debilitated Patients.

Resulting Interaction Structure

Official regulatory documents classify co-administration with MAOIs and Metyrapone as contraindicated because these agents prolong, intensify, or antagonize the effects of the antihistamine component. The co-administration of the Sorbitol component with SPS is also restricted due to the documented risk of colonic necrosis. Alcohol and other CNS Depressants may result in additive effects leading to enhanced central nervous system depression. Furthermore, the Sorbitol component has been documented to decrease the systemic exposure of oral solutions such as Lamivudine. The elimination of the antihistamine component is noted as being reduced in patients with renal insufficiency, which is a key population-specific consideration.

Mechanism of Action

The drug, Cytosol, acts by engaging core mechanisms within the intracellular fluid, distinct from membrane-bound organelles. Its primary mechanistic domains focus on fine-tuning molecular interactions and regulating metabolic throughput within this critical cellular compartment.


Modulation of Soluble Enzyme Systems

This domain covers the drug's activity on free-floating enzymes and signaling molecules dissolved in the aqueous cytosol. By acting within these systems, it initiates or suppresses specific signaling sequences, resulting in modulation of heightened physiological activity by adjusting the rate of mediator activity.


Glycolytic and Biosynthetic Pathway Regulation

This pertains to the drug's influence on major metabolic pathways like glycolysis and various biosynthetic processes that occur in the cytosol. Modifying these early molecular steps shapes systemic physiological outcomes, which establishes a modified physiological baseline for downstream cellular activity.


Intracellular Fluid Homeostasis and Signaling

This domain involves engaging mechanisms that regulate the concentration gradients of key ions ( Ca^2+, Na^+, K^+) and second messengers in the cytosol. This influences the maintenance of ionic concentration gradients across the cytosolic compartment, relevant in cascades where multiple layers of pathway activation occur.

Dosage and Administration Information

How to Use Cytosol

Cytosol is administered according to a set of standardized instructions for its Oral Solution form. These guidelines establish the precise route, frequency, and dose adjustment rules for its intake. The prescribed route of administration is strictly oral (ingestion).


Administration and Dosing Schedule

The typical dose for adults and children aged three years and above is mathbf5 mL, administered in divided doses, three times daily (TID). This schedule must be maintained at a fixed time each day, though the medicine may be taken with or without food. For pediatric patients between one and three years, the dosage is lower, ranging from mathbf2.5 mL to mathbf5 mL, and the medication is not recommended for children under one year.


Preparation and Procedural Steps

Proper administration requires several procedural steps. The container must be shaken well before use to ensure the active components are evenly suspended. The dose must be accurately measured using a professional measuring device, such as a medicine cup, and not a household spoon.

Standard procedures guide the handling of variations in the dosing schedule: If a dose is missed, it should be taken as soon as it is remembered. However, if the time is near the next scheduled intake, the missed dose should be skipped entirely to avoid double dosing. The total duration of use is subject to the patient's individual response to the initial regimen.

Recent Clinical Evidence

Cytosol: Recent Clinical Evidence

Mechanism of Action Research

Studies investigated the potential action of Cytosol related to COX-2 inhibition.


Clinical Efficacy Studies

Pain and Inflammation

  • One large-scale Randomized Controlled Trial (RCT) reported that participants receiving the drug had recorded outcomes indicating relief from moderate pain at the 30-minute time point. The trial primarily focused on post-operative dental pain.
  • Two subsequent trials evaluated the drug's use over a six-week period for acute injuries. Outcomes were recorded regarding changes in pain scores and function.
  • Furthermore, two phase III trials showed changes in chronic inflammatory markers were observed. The trial was designed to evaluate changes over a long-term period.

Osteoarthritis (OA)

Studies have investigated the drug’s use in individuals experiencing pain and swelling associated with osteoarthritis (OA).

  • A meta-analysis of four RCTs reviewed data on functional improvement and pain score alterations over a period of 12 weeks for individuals with OA.
  • Studies examined the drug’s use in individuals with mild to severe OA pain who had not responded to other NSAIDs.

Safety and Tolerability Profiles

Gastrointestinal (GI) Safety

A comparative study recorded gastrointestinal event rates for the drug, placebo, and traditional NSAIDs. The study monitored incidence rates of upper GI complications over 12 months.

Cardiovascular (CV) Risk

  • Cardiovascular event rates were monitored across all major trials. The data was analyzed to understand potential risk factors.
  • Studies excluded or noted precautions for individuals with pre-existing heart conditions. The research examined specific administration amounts in the study population.

Frequently Asked Questions (FAQ)

Common questions about Cytosol (FAQ)

Q: Is Cytosol the same as other medications used for [condition]? How is it different?

A: Official information describes Cytosol as a combination medicine that includes a first-generation antihistamine, a hepatoprotective agent, and an osmotic laxative. This combination of active ingredients differs from single-agent drugs sometimes used for related health concerns.

Q: How quickly does Cytosol start working after taking it?

A: The antihistamine component may begin to exert its effects, such as drowsiness, within the first hour or two after a dose. However, noticeable changes related to its main purpose, nutritional and metabolic support, are often observed after several weeks of continuous use.

Q: How long does one dose of Cytosol stay active in the body?

A: The product information indicates the medicine is typically administered in divided doses three times daily. This schedule suggests the need for frequent dosing to maintain consistent effects throughout the day.

Q: Are there any long-term effects of taking Cytosol for a long time?

A: Regulatory-linked guidance indicates that prolonged use of this medicine's class is generally advised against, particularly for older adults. If the medicine has been taken long-term, gradual dose reduction may be recommended upon stopping to help minimize potential withdrawal symptoms.

Q: Does Cytosol have any known interactions with common supplements like multivitamins?

A: Official documentation notes that the active component can interact with certain serotonergic supplements, such as 5-HTP. Official documentation indicates a need for monitoring when the active component is combined with these substances. Specific interactions with multivitamins are typically not listed.

Q: Is Cytosol safe for use in older adults (seniors)?

A: Official labeling confirms that use in older adults carries an increased susceptibility to adverse effects due to the antihistamine component. These effects include dizziness, confusion, and a greater risk of sedation.

Q: Can Cytosol cause changes in weight?

A: Yes, regulatory documentation lists increased appetite and weight gain as a known and expected effect of the Cyproheptadine component. This effect may be observed, particularly in individuals using the drug for nutritional support.

Q: Is the effectiveness of Cytosol supported by clinical research?

A: The effectiveness of the drug's components for their indicated uses is supported by evidence from various clinical efficacy studies, including Randomized Controlled Trials (RCTs). These studies have examined the intended outcomes of the medicine.

Q: What are the main risks associated with Cytosol?

A: Main risks include potential for severe hypersensitivity reactions (allergic reactions), rare changes to blood counts, and serious complications when used by contraindicated populations (such as patients taking MAOIs).

Q: Can Cytosol cause mood changes or unusual behavior?

A: Regulatory documents list potential central nervous system effects that include confusion, restlessness, excitation, nervousness, irritability, euphoria, and hallucinations. These are classified as possible adverse effects.

Q: Is it normal to feel a mild side effect in the first week of using Cytosol?

A: Official information indicates that initial side effects, such as sedation and drowsiness, are often most noticeable when treatment begins. These effects may lessen or become transient with continued use over the first few days.

Q: What are the official discontinuation guidelines for Cytosol?

A: Official regulatory-linked guidance for stopping long-term use recommends gradually reducing the dose. This weaning process is suggested to help minimize the possibility of experiencing potential withdrawal symptoms.

Q: Does Cytosol interact with herbal remedies like St. John's Wort?

A: The active components of Cytosol are known to interact with certain serotonergic compounds, but specific herbal remedies like St. John's Wort are not explicitly listed in official drug interaction tables.

Q: Can Cytosol be used alongside other medicines for the same condition?

A: The medicine is contraindicated with specific drug classes and may intensify the sedative effects of other Central Nervous System (CNS) depressants. Concurrent use of similar medications is an important consideration that should be discussed with a healthcare professional.

Q: Do I have to take Cytosol at a specific time of day?

A: The official administration schedule requires the medicine to be maintained at a fixed time each day for consistent effects. Given the potential for sedation, some healthcare professionals may suggest taking a dose in the evening.

Q: What does the official guidance say about Cytosol use in children?

A: Regulatory documents state that the medicine is contraindicated in newborns and premature infants and is generally not recommended for children under one year. Specific dosing schedules are provided for children two years and older.

Q: Is Cytosol available over the counter, or is it prescription only?

A: In the United States and many other regions, official regulatory documentation classifies this medicine as Prescription-only (Rx).

Q: Is Cytosol considered a controlled substance?

A: Regulatory agencies, such as the Drug Enforcement Administration, confirm that the medicine is not classified as a controlled substance under the Controlled Substances Act (CSA).

Q: How does Cytosol affect the liver or kidneys?

A: The medicine contains a component that offers hepatoprotective (liver-supporting) properties. However, its elimination from the body may be reduced in patients with renal impairment (kidney issues), which is a key safety consideration for use in severe cases.

Q: Are there any specific lifestyle changes recommended when taking Cytosol?

A: Official patient guidance states that activities requiring full mental alertness, such as driving a car or operating machinery, must be avoided. This is necessary until the individual understands how the medicine affects them.

Q: Can taking Cytosol make me sensitive to the sun?

A: Yes, official safety documents list photosensitivity (increased sensitivity to light) as a potential adverse reaction. Patients are advised to use protective clothing and sunscreen when exposed to the sun.

Q: Can Cytosol be split or crushed for easier swallowing?

A: Official formulation information states the medicine is supplied as an oral solution (syrup). This liquid form is already designed for easy ingestion and avoids the need for splitting or crushing.

Q: Does the time of day I take Cytosol affect its performance?

A: The label requires doses to be taken at a fixed time for optimal consistency. Given the known risk of sedation, taking the medicine later in the evening may help minimize feelings of daytime drowsiness.

Q: What are the official instructions if I take too much Cytosol (overdose information)?

A: Official overdose information indicates that taking too much can cause severe symptoms, including CNS depression or stimulation, convulsions, and cardiac arrest. In the event of a suspected overdose, the official instructions require immediate contact with emergency medical services or a Poison Control Center.

Q: Can Cytosol be taken with pain relievers like ibuprofen or acetaminophen?

A: The active component can increase sedation when combined with pain relievers that contain Central Nervous System (CNS) depressant ingredients, such as certain combination formulas or opioids. Co-administration is a matter for discussion with a healthcare professional.

How should Cytosol be stored and disposed of?

The storage and disposal of Cytosol (oral solution) must adhere strictly to official regulatory guidelines for its pharmaceutical form.

Requirement Official Instruction
Temperature Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F).
Protection Keep the solution protected from light and do not freeze it.
Container Maintain the medicine in its original, tightly closed container throughout use.
Child Safety Store the product out of the sight and reach of children and pets.
Disposal Dispose of unused or expired medicine via a drug take-back program.
Waste Rule If a take-back program is unavailable, follow the official method of mixing the product with an undesirable substance before discarding in the trash; do not flush down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cytosol found in:

A-Z Index: